Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. (PIRS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pirs · stock forecast · 2 analysts (3M) · FMP · updated Feb 11, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $13.60
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $13.52 | ↓ 0.61% |
1-day model range: $13.29–$13.74. Peak: $13.74 (-0.61%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · PIRS · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2020-03-13 | Baird | Upgrade ↑ | Neutral→Outperform |
| 2020-03-12 | Baird | Upgrade ↑ | Neutral→Outperform |
| 2019-07-30 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2019-07-29 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2016-03-09 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2016-03-08 | JMP Securities | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Pieris Pharmaceuticals, Inc. (PIRS) stock. Of the recent 6 rating actions, 2 were upgrades and 2 were downgrades. 2 analysts currently cover PIRS.
Analyst Recommendation Trends
PIRS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$27M
↑ 301.0% YoY
Revenue Next Year
$32M
↑ 20.4% YoY
EPS This Year
$-50.74
EPS Next Year
$-28.00
↓ 44.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast PIRS EPS of $-50.74 for the current fiscal year, based on estimates from 1 analysts. The PIRS revenue forecast is $27M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PIRS stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PIRS price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The PIRS short-term stock prediction for tomorrow is $13.52 (-0.61%).
Pieris Pharmaceuticals, Inc. trades on NASDAQ under the ticker PIRS. The PIRS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
PIRS forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month PIRS price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $13.60.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.